Vanessa Laversenne

This study demonstrates that deep PrP lowering with a potent siRNA prevents prion disease symptoms in mice and extends survival in symptomatic animals.

The paper identifies two small molecules that lower PrP levels in cultured cells but show limited activity in human cell lines and in vivo.

The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.

Divalent siRNA 2439-s4 lowers human PrP to 17% residual in transgenic mouse brain after one dose, and a separate mouse Prnp-targeting siRNA extends survival in prion-infected mice.

This study demonstrates that Zinc Finger Repressors (ZFRs) reduce prion protein (PrP) expression in nonhuman primates and extend survival in prion disease mice.

This study shows that AMPK enhances associative learning in C. elegans by promoting neuronal mitochondrial fusion, which is critical for maintaining neuronal function with age and in neurodegenerative conditions.